An International, Randomised, Double-Blind, Two-Arm Study to Evaluate the Safety and Efficacy of Vandetanib 150 and 300mg/day in Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma with Progressive or Symptomatic Disease
10 countries, 34 sites plus seven back-up sites
Hopefully five UK centres – Cardiff, Christie, Royal Marsden, Barts and Newcastle – will be taking part
80 patients required, 14 months recruitment period expected
Inclusion Criteria of Interest:
- Confirmed histological diagnosis of MTC
- Unresectable locally advanced and/or metastatic
- Hereditary or sporadic
- Objective disease progression within the previous 14 months and/or Symptomatic
Currently awaiting MREC and MHRA approval in the UK so recruitment may be able to commence in June/July 2012
[April 2012]